Xinjiang Baihuacun Pharmaceutical Group

Xinjiang Baihuacun Pharmaceutical Group is a China-based company primarily engaged in providing pharmaceutical research and development services. Following a significant strategic pivot from the commercial retail sector, the company established itself as a leading Contract Research Organization (CRO) through the acquisition of Beijing Huasheng Pharmaceutical. Its core business encompasses the entire drug development lifecycle, including pharmaceutical chemistry, formulation development, clinical trial management, and regulatory affairs. The group specializes in the development of generic drugs and high-end formulations, serving a broad client base within the Chinese domestic market. Listed on the Shanghai Stock Exchange, it operates as a comprehensive platform for pharmaceutical innovation and technical services.